Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Capital from the financing will advance development of SYNT, an orally delivered, transient polymer coating for the small intestine that controls nutrient uptake, enhances gut-restricted enzyme efficacy, and increases systemic drug absorption for up to 24 hours.
The funding also enables the advancement of lead program SYNT-101 through Phase 1 studies as a once-daily treatment for obesity, as well as initiation of Phase 1 studies for SYNT-202, a first-in-class oral enzyme therapy for homocystinuria, a rare pediatric amino acid disorder.
Read more about the financing here.
The Mintz team included Members Joshua Fox and Alexander Civetta as well as Associates Danielle Barney and Libby Decker.